Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03833115
Other study ID # CRI-INV.15
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 23, 2018
Est. completion date December 4, 2020

Study information

Verified date February 2021
Source Laval University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

There is an urgent need to develop non-hormonal innovative preventive measures under the control of women that can prevent unintended pregnancy. Based on our experimental data, the use of a gel formulation containing SLS could represent a potent and safe topical vaginal spermicide. The impact of such a preventive tool on public health will be enormous. After successfully completing supportive Phase I/II safety trials, the next step is a prospective pilot clinical trial to evaluate the safety and effectiveness of our gel formulation as a spermicidal agent and for preventing unintended pregnancy in healthy women.


Description:

Study objectives (Outcomes): The primary objective (Primary outcome) of this clinical trial is to evaluate the spermicidal efficacy in vitro and in post-coital test of gel formulation containing or not 2% SLS, when applied once intravaginally in healthy volunteers (women with their stable male sexual partners). The secondary objective (Secondary outcome) of the study is to evaluate the safety and preliminary efficacy in preventing pregnancy of the gel formulation containing 2% SLS when used repeatedly before each sexual intercourse for a period of 3 months. Study design: Pilot trial First phase- During volunteers screening for eligibility, male sexual partners will submit sperm samples; half of the sperm sample will be used for spermogram, and the other half of the sperm sample will be used (if normal spermogram) for in vitro testing of the spermicidal efficacy of the gel formulation components. If eligible, the man and his eligible female sex partner will be enrolled. Eligible women of the eligible male sex partners will have one vaginal gel application up to 30 min before planned sexual intercourse (vaginal penile penetration) with male ejaculating inside the vagina. Women will come to the clinic within a maximum of 12h period after the sexual intercourse for post-coital test. The gel must not be applied during menstrual period. The use of other vaginal products and male condom by participants is prohibited during the study period. A diary will be given to participants to record information concerning the internal use, if any, of any vaginal product (including tampons). This pilot trial will be performed in 1 center at the facilities of the Clinical Research of the CHU de Québec-Université Laval, CHUL. Second phase- Couples agreeing to use the product repeatedly will continue to use the gel-SLS before each and every sexual intercourse, except during menstruation, for a period of 3 months. Women will report safety parameters after each vaginal use of the gel-SLS and will be followed regularly at the facilities of the Clinical Research of the CHU de Québec-Université Laval, CHUL.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date December 4, 2020
Est. primary completion date December 4, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria: Woman 1. Healthy woman seeking to space or delay pregnancy aged between 18 and 49 years 2. Sexually active 3. Willing to give written informed consent to participate in the trial 4. Normal physical and gynecological examination 5. Negative urine pregnancy test at screening 6. Willing to engage in planned heterosexual vaginal intercourse with ejaculation inside the vagina 7. Female participant in first phase of the study must be already using and agreeing continuous use of a reliable method of contraception defined as use of hormonal contraception (pill, patch or injection, in accordance with the approved product label) during treatment with the study product and must agree to maintain the contraceptive method for at least 2 weeks after discontinuation of study product if not participating in second phase of the study. If the female participant participates in the second phase of the study, she must stop using the method of contraception during product application and use only the test product provided (vaginal gel-SLS). Man 1. Healthy man aged 18 years and older 2. Sexually active 3. Normal spermogram at inclusion 4. Normal physical examination 5. Willing to give written informed consent to participate in the trial 6. Willing to engage in planned heterosexual vaginal intercourse with ejaculation inside the vagina for post coital test. Exclusion Criteria: Woman 1. Abnormal physical/gynecological examination 2. Pregnant at enrolment 3. Lactating or breastfeeding 4. History of vaginitis during the last 3 months 5. History of using vaginal medications during the last 3 months 6. History of STIs (genital herpes, HIV, gonorrhea, chlamydiasis, syphilis, vulvo-vaginal or cervical HPV) during the last 12 months 7. STIs at time of screening 8. Abnormal laboratory findings with clinical significance 9. Allergy to applicator material (polyethylene), to gel polymer (polyoxyethylene-polyoxypropylene) 10. History of toxic shock syndrome (TSS) 11. Use of other contraceptive methods during the study period other than the ones accepted in the study including intrauterine device (IUD), diaphragm, spermicide, contraceptive ring and fertility awareness methods (first phase of the study, no contraception during the second phase) 12. Post-menopausal (12 months of spontaneous amenorrhea and =40 years of age) or physically incapable of becoming pregnant with documented permanent sterilization or history of infertility without anterior pregnancy. 13. Women seeking for efficient contraception 14. Current enrolment in any other clinical trial involving investigational drug, vaccine or medical device. 15. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol specified assessments. Man 1. Abnormal physical examination 2. Abnormal spermogram 3. Surgical sterilization 4. History of urinary infections during the last 3 months 5. History of STIs (genital herpes, HIV, gonorrhea, chlamydiasis, syphilis, HPV) during the last 12 months 6. STIs at time of screening 7. Abnormal laboratory findings with clinical significance 8. Allergy to gel polymer (polyoxyethylene-polyoxypropylene) 9. Current enrolment in any other clinical trial involving investigational drug, vaccine or medical device. 10. Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol specified assessments.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
vaginal gel containing or not sodium lauryl sulfate
Prevention

Locations

Country Name City State
Canada Michel Bergeron Quebec

Sponsors (1)

Lead Sponsor Collaborator
Laval University

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Measuring motility of spermatozoides in vitro in presence of gel or gel-SLS, and in post-coital test after using gel or gel-SLS First, the motility of spermatozoides (progressive, non-progressive, or non-motile) in vitro in presence of gel, gel-SLS will be measured.
Second, the motility of spermatozoides in post-coital test after single intravaginal application of gel or gel-SLS will be measured in women.
3-6 months
Secondary Recording pregnancy occurrence after using gel-SLS Recording pregnancy (no. of pregnant women) after the intravaginal application of the gel-SLS before each sexual intercourse for a period of 3 months. 3 months
Secondary Recording adverse events (AE) after using gel-SLS Recording AE (general and genital AE) after the intravaginal application of the gel-SLS before each sexual intercourse for a period of 3 months. 3 months
See also
  Status Clinical Trial Phase
Completed NCT02577601 - Impact of Combined Hormonal Contraceptives on UPA Phase 4
Completed NCT03153644 - Improving Contraceptive Care for Women With Medical Conditions
Completed NCT04112095 - Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use Phase 3
Recruiting NCT05521646 - Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative N/A
Active, not recruiting NCT04291001 - Ovarian Function With ENG Implant and UPA Use Early Phase 1
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Completed NCT03438682 - Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
Active, not recruiting NCT01948882 - Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women N/A
Enrolling by invitation NCT04997499 - Adolescent Subcutaneous (SQ) Injection Video Validation N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03154125 - Sayana® Press Extension Study Phase 3
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT02957630 - "E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study" Phase 1/Phase 2
Completed NCT02456584 - Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods Phase 1
Completed NCT02718222 - Impact and Performance of Institutionalizing Immediate Post-partum IUD Services N/A
Recruiting NCT02121067 - LNG-IUS at 2 Weeks Postpartum Phase 4
Terminated NCT02169869 - Immediate Postplacental IUD Insertion N/A
Recruiting NCT02292056 - Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions N/A
Withdrawn NCT01930994 - Kenya Sino-implant (II) PK Study N/A